PIEPOC: A new prognostic index for advanced epithelial ovarian cancer - Japan Multinational Trial Organization OC01-01

被引:36
作者
Teramukai, Satoshi
Ochiai, Kazunori
Tada, Harue
Fukushima, Masanori
机构
[1] Kyoto Univ Hosp, Translat Res Ctr, Dept Clin Trial Design & Management, Sakyo Ku, Kyoto 6068507, Japan
[2] Jikei Univ, Sch Med, Dept Gynecol, Tokyo, Japan
关键词
D O I
10.1200/JCO.2007.11.0114
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
Purpose The purpose of this study was to construct a simple and powerful prognostic index ( PI) of epithelial ovarian cancer, the PIEPOC. Patients and Methods In a retrospective review, data from 768 women with stage III or IV epithelial ovarian cancer from 24 institutions in Japan were evaluated for clinical features predictive of overall survival. A PI and risk groups to predict overall survival after initial surgery were developed using the proportional hazards regression model. Results Of six factors, the four prognostic factors that remained independently significant in the analysis of a training sample ( 538 randomly selected patients) were age, performance status ( PS), histologic cell type, and residual tumor size. From the regression function, we derived a PI = 1 ( if age 70 and above) = 1 ( if PS 1 or 2) + 2 ( if PS 3 or 4) + 1 ( if mucinous or clear-cell) + 2 ( if residual size 0.1 cm and above). Patients were classified into three risk groups ( PIEPOC): low risk ( PI 0-2), intermediate risk ( PI 3), and high risk ( PI 4-6). The PIEPOC was equally predictive in a validation sample ( n = 230), identifying three groups ( 5-year survival: 0.67 in low, 0.43 in intermediate, 0.17 in high risk). Conclusion Our proposed PI, the PIEPOC, was predictive in our patient population and may have utility in clinical practice. Prospective studies would be needed to confirm the prognostic predictive ability of the PIEPOC for patients with advanced epithelial ovarian cancer.
引用
收藏
页码:3302 / 3306
页数:5
相关论文
共 18 条
[1]
Akaike H, 1973, 2 INT S INFORM THEOR, P199, DOI 10.1007/978-1-4612-1694-0
[2]
Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: A meta-analysis [J].
Bristow, RE ;
Tomacruz, RS ;
Armstrong, DK ;
Trimble, EL ;
Montz, FJ .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (05) :1248-1259
[3]
Advances in ovarian cancer chemotherapy [J].
Deppe, G ;
Baumann, P .
CURRENT OPINION IN ONCOLOGY, 2000, 12 (05) :481-491
[4]
Harrell FE, 1996, STAT MED, V15, P361, DOI 10.1002/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO
[5]
2-4
[6]
Holschneider CH, 2000, SEMIN SURG ONCOL, V19, P3, DOI 10.1002/1098-2388(200007/08)19:1<3::AID-SSU2>3.0.CO
[7]
2-S
[8]
Ioka A, 2003, CANCER SCI, V94, P292
[9]
Assessing the generalizability of prognostic information [J].
Justice, AC ;
Covinsky, KE ;
Berlin, JA .
ANNALS OF INTERNAL MEDICINE, 1999, 130 (06) :515-524
[10]
LUND B, 1990, CANCER RES, V50, P4626